Details

Autor(en) / Beteiligte

• Suntsova, Elena V.
• Maschan, Alexey A.
• Baydildina, Dina D.
• Kalinina, Irina I.
• Petrova, Uliana N.
• Pshonkin, Alexey V.
• Novichkova, Galina A.

Titel

Thrombopoietin receptor agonist switch in children with persistent and chronic severe immune thrombocytopenia: A retrospective analysis in a large tertiary center

Ist Teil von

• Pediatric blood & cancer, 2019-06, Vol.66 (6), p.e27704-n/a

Ort / Verlag

United States

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• We retrospectively analyzed sequential therapy with romiplostim and eltrombopag in 23 children with immune thrombocytopenia: switching from romiplostim to eltrombopag (10 patients) or vice versa (13 patients). The median age of patients at enrollment in the study was 5.6 years (2‐15 years). Switching from romiplostim to eltrombopag was effective in eight (80%) patients, whereas switching from eltrombopag to romiplostim was effective in eight (62%) patients. The response rate was similar in patients failing the first thrombopoietin receptor agonist and those who had previous response. To date, all responders continue to maintain platelets over 50 × 109/L at 13‐39 months after switching.